4/22
04:46 pm
edit
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
Medium
Report
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
4/22
04:31 pm
edit
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Low
Report
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
4/8
10:07 am
edit
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer [Yahoo! Finance]
Low
Report
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer [Yahoo! Finance]
3/29
12:57 pm
edit
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? [Yahoo! Finance]
3/20
04:16 pm
edit
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]
Low
Report
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]
3/7
03:42 am
edit
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. [Yahoo! Finance]
Low
Report
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. [Yahoo! Finance]
3/6
12:03 am
edit
Insider Sells Shares of Editas Medicine Inc (EDIT) [Yahoo! Finance]
Low
Report
Insider Sells Shares of Editas Medicine Inc (EDIT) [Yahoo! Finance]
3/4
10:49 am
edit
1 Beaten-Down Stock With 55% Upside, According to Wall Street [Yahoo! Finance]
Low
Report
1 Beaten-Down Stock With 55% Upside, According to Wall Street [Yahoo! Finance]
3/2
10:02 pm
edit
Why Editas Medicine Stock Soared as Much as 42% Higher This Week [Yahoo! Finance]
Medium
Report
Why Editas Medicine Stock Soared as Much as 42% Higher This Week [Yahoo! Finance]
3/2
07:28 am
edit
Editas Medicine, Inc. (NASDAQ:EDIT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
Medium
Report
Editas Medicine, Inc. (NASDAQ:EDIT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]
3/1
02:04 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/29
12:33 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target raised by analysts at Citigroup Inc. from $11.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target raised by analysts at Citigroup Inc. from $11.00 to $16.00. They now have a "buy" rating on the stock.
2/29
11:30 am
edit
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/29
09:10 am
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target raised by analysts at Barclays PLC from $10.00 to $11.00. They now have an "equal weight" rating on the stock.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target raised by analysts at Barclays PLC from $10.00 to $11.00. They now have an "equal weight" rating on the stock.
2/28
09:33 am
edit
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
Neutral
Report
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
2/28
07:00 am
edit
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
High
Report
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
2/27
01:41 pm
edit
Global Genome Editing Market to Reach US$ 26.5 Billion by 2034 at a CAGR of 15.7%: A Revolution in Biomedicine | Future Market Insights Inc. [Yahoo! Finance]
Low
Report
Global Genome Editing Market to Reach US$ 26.5 Billion by 2034 at a CAGR of 15.7%: A Revolution in Biomedicine | Future Market Insights Inc. [Yahoo! Finance]
2/27
01:08 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target raised by analysts at JPMorgan Chase & Co. from $8.00 to $9.00. They now have a "neutral" rating on the stock.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target raised by analysts at JPMorgan Chase & Co. from $8.00 to $9.00. They now have a "neutral" rating on the stock.
2/22
11:05 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/21
07:00 am
edit
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
Low
Report
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
2/19
11:53 am
edit
Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade [Yahoo! Finance]
2/9
10:02 pm
edit
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
2/6
01:35 pm
edit
What Makes Editas (EDIT) a New Buy Stock [Yahoo! Finance]
Low
Report
What Makes Editas (EDIT) a New Buy Stock [Yahoo! Finance]
1/31
09:00 am
edit
Editas Medicine to Participate in Upcoming Investor Conferences
Medium
Report
Editas Medicine to Participate in Upcoming Investor Conferences